Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial

BACKGROUND: This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes lacking an apparent history of cardiovascular disease. METHODS: This was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Katakami, Naoto, Mita, Tomoya, Yoshii, Hidenori, Shiraiwa, Toshihiko, Yasuda, Tetsuyuki, Okada, Yosuke, Kurozumi, Akira, Hatazaki, Masahiro, Kaneto, Hideaki, Osonoi, Takeshi, Yamamoto, Tsunehiko, Kuribayashi, Nobuichi, Maeda, Kazuhisa, Yokoyama, Hiroki, Kosugi, Keisuke, Ohtoshi, Kentaro, Hayashi, Isao, Sumitani, Satoru, Tsugawa, Mamiko, Ryomoto, Kayoko, Kato, Ken, Nakamura, Tadashi, Kawashima, Satoshi, Sato, Yasunori, Watada, Hirotaka, Shimomura, Iichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286339/
https://www.ncbi.nlm.nih.gov/pubmed/37349722
http://dx.doi.org/10.1186/s12933-023-01879-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286339/
https://www.ncbi.nlm.nih.gov/pubmed/37349722
http://dx.doi.org/10.1186/s12933-023-01879-4

Ejemplares similares